Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401812 | 1.00 | KIF11 (0.50) | KIF11MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL27685329 | 1.00 | KIF11 (0.50) | KIF11MAPTKMT2ACYP1A2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL919041 | 0.91 | KIF11 (0.44) | KIF11MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL21086711 | 0.86 | MAPT (0.48) | KIF11MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL4399040 | 0.84 | KIF11 (0.45) | KIF11MAPTALDH1A1PTGS1 | |
| SCHEMBL4399038 | 0.84 | KIF11 (0.45) | KIF11MAPTALDH1A1PTGS1 | |
| SCHEMBL6910253 | 0.84 | KIF11 (0.50) | KIF11MAPTALDH1A1PTGS1 | |
| SCHEMBL5281006 | 0.83 | MAPT (0.55) | KIF11MAPTKMT2ACYP1A2CYP2D6 | |
| SCHEMBL23176910 | 0.82 | KIF11 (0.45) | KIF11MAPTALDH1A1PTGS1 | |
| SCHEMBL6670880 | 0.82 | KIF11 (0.45) | KIF11MAPTKMT2ACYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| CN-117836270-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-0575844-B1 | Hydroxamic acid derivatives and pharmaceutical compositions thereof | HOFFMANN LA ROCHE (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | KIF11 4542/4885MAPT 4425/4885KMT2A 3703/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | KIF11 2486/4885MAPT 2094/4885KMT2A 2112/4885 |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | EPCAM, SELPLG, VCAM1 | KIF11 3614/4885MAPT 2502/4885KMT2A 3166/4885 |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | KIF11 2181/4885MAPT 2434/4885KMT2A 955/4885 |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ANXA7, GRB7 | KIF11 3278/4885MAPT 2503/4885KMT2A 4248/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | KIF11 2982/4885MAPT 2830/4885KMT2A 496/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | KIF11 841/4885MAPT 3370/4885KMT2A 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.